Literature DB >> 1869055

Threshold Amsler grid testing in diabetic retinopathy.

K A Wolfe1, A A Sadun.   

Abstract

The Amsler grid is a suprathreshold target used to assess the central 10 degrees of the visual field; thus, it may fail to detect relative central scotomas. Low luminance conditions can be created by viewing the white grid on a black background through two cross-polarizing filters that vary light transmission and change the procedure to a threshold Amsler grid (TAG) test, thereby increasing its sensitivity. A total of 26 patients with diabetic retinopathy were tested by standard Amsler grid, TAG, and tangent screen. Four scotomas were detected by Amsler grid testing; each of these scotomas expanded in size on retesting with the TAG. TAG testing revealed 22 scotomas more than five times the number seen with conventional Amsler grid testing; tangent-screen examination confirmed 9 of these defects. In many cases, fundus photography and fluorescein angiography revealed pathology that correlated with the scotomas detected only by TAG testing. It thus appears that the TAG test is a rapid, high-yield, and sensitive means of assessing the central visual field in patients with diabetic retinopathy.

Entities:  

Mesh:

Year:  1991        PMID: 1869055     DOI: 10.1007/bf00167871

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

1.  Earliest symptoms of diseases of the macula.

Authors:  M AMSLER
Journal:  Br J Ophthalmol       Date:  1953-09       Impact factor: 4.638

2.  Threshold Amsler grid testing. Cross-polarizing lenses enhance yield.

Authors:  M Wall; A A Sadun
Journal:  Arch Ophthalmol       Date:  1986-04

3.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

4.  Diabetic macular edema. A review.

Authors:  G H Bresnick
Journal:  Ophthalmology       Date:  1986-07       Impact factor: 12.079

5.  Brightness-sense and optic nerve disease.

Authors:  A A Sadun; S Lessell
Journal:  Arch Ophthalmol       Date:  1985-01

6.  Threshold Amsler grid testing in maculopathies.

Authors:  M Wall; D R May
Journal:  Ophthalmology       Date:  1987-09       Impact factor: 12.079

7.  Low-intensity grids improve sensitivity of amsler grid testing in diabetic patients without background retinopathy.

Authors:  M Wall; C Collins; D R May
Journal:  Ann Ophthalmol       Date:  1990-03

8.  Macular edema and cystoid macular edema.

Authors:  B S Fine; A J Brucker
Journal:  Am J Ophthalmol       Date:  1981-10       Impact factor: 5.258

9.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

  9 in total
  6 in total

Review 1.  The Amsler chart: absence of evidence is not evidence of absence.

Authors:  Michael Crossland; Gary Rubin
Journal:  Br J Ophthalmol       Date:  2007-03       Impact factor: 4.638

2.  Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.

Authors:  Patrizio Tatti; Franco Arrigoni; Adriano Longobardi; Flavia Costanza; Patrizia Di Blasi; Domenico Merante
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 3.  Paradigm Shifts in Ophthalmic Diagnostics.

Authors:  J Sebag; Alfredo A Sadun; Eric A Pierce
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

4.  Quantitative analysis of central visual field defects in macular edema using three-dimensional computer-automated threshold Amsler grid testing.

Authors:  Renu V Jivrajka; Janet K Kim; Wolfgang Fink; Alfredo A Sadun; J Sebag
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-29       Impact factor: 3.117

Review 5.  Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.

Authors:  Pearse A Keane; Gabriella de Salvo; Dawn A Sim; Srini Goverdhan; Rupesh Agrawal; Adnan Tufail
Journal:  Clin Ophthalmol       Date:  2015-02-17

6.  M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections.

Authors:  Katarzyna Nowomiejska; Agnieszka Oleszczuk; Agnieszka Brzozowska; Andrzej Grzybowski; Katarzyna Ksiazek; Ryszard Maciejewski; Piotr Ksiazek; Anselm Juenemann; Robert Rejdak
Journal:  BMC Ophthalmol       Date:  2013-04-15       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.